Hand, foot and mouth disease enters a high-risk period, the relevant medical concept unit is concerned

Pharmaceutical Network Industry Dynamic" April to July is the high incidence of hand, foot and mouth disease, which is a common acute infectious disease in infants and young children under 5 years of age, caused by a variety of enterovirusesThe 2018 National Report on Statutory Infectious Diseases shows that the number of cases of hand, foot and mouth disease is the highest among the total number of cases at 2.376 millionAt present, there is no specific treatment before hand, foot and mouth, the more effective response is vaccination, do a good job of prevention, in addition to the need to wash hands frequently, eat cooked food, strengthen exercise and so onwith hand, foot and mouth disease into the high-risk period, the relevant pharmaceutical sector has also been concerned, the industry said, some concept stocks such as Zhifei Bio, Haichen Pharmaceuticals, Watson Bio, Antu Bio, etc., in the later or ushered in a good performancepublic information shows that in March 2016, China's hand, foot and mouth disease vaccine EV71 vaccine was officially approved for the marketKexing Bio and the Institute of Medical Biology of the Chinese Academy of Medical Sciences, Kunming Institute of two institutions have isolated key virus strains, developed vaccines and successively listedAs of January 2019, there are three manufacturers of EV71 vaccines approved for the market: the Institute of Medical Biology of the Chinese Academy of Medical Sciences (Kunming Institute), Beijing Kexing Bio and Wuhan InstituteThe results of clinical trials of EV71 vaccineI, II and III show that the vaccine has good immunogenicity and protection, and has good safetyThe EV71 vaccine has also become an important means of preventing EV71 infection and hand, foot and mouth diseaseIn 2018, the total number of batches of this type of vaccine was issued to more than 27 million dosesin addition to these three manufacturers, at present, Zhifei Bio co-developed to develop also includes hand, foot and mouth disease vaccineIn January 2019, The inactivated type 71 enterovirus type 71 vaccine of Zhifei Green Bamboo, a wholly owned subsidiary of Zhifei Bio, was also approved by the State Drug Administration for clinical trials of drugs, which agreed to conduct clinical trials of the productWatson Bio's recombinant enterovirus type 71 virus-like particle vaccine (Beech yeast) is also used to prevent hand, foot and mouth disease caused by EV71 virus infection, the company has filed a clinical research registration application with the State Drug Administration on March 11, 2019, and obtained the State Drug Administration issued a "notice of acceptance."in addition, Haichen Pharmaceutical's monocytoglyged inthesofed, clinically mainly used to treat chronic hepatitis B and other infections such as shingles, herpes simplex, etc, in addition to hand, foot and mouth disease and children's chickenpox also have a certain effect Guizhou Three Forces fist products open throat sword spray (child type) for oral throat disease drugs rarely used in children's drugs, in 2009 into the national medical insurance catalog Class B catalog, so far now cover edgy the country's second-level and above hospitals more than 3500, listed for more than ten years, hand-foot-mouth disease, pharyngitis, tonsillitis and other children common respiratory infection treatment has a clear advantage, and similar products apply more widely It is understood that spray administration can reduce the liver burden of drug metabolism in children patients, direct absorption, fast effect, high efficacy, short course of treatment Antu bio has a certain microbial testing reagent production capacity and technical process According to the annual report estimates, the current Antu biochemical luminosis instrument output of about 300,000 yuan, superposition instruments quickly launched, the future is expected to accelerate the growth of performance In 2019, the company's biochemical immuno-microbial reagent sales increased by 16%, 16% and 27% year-on-year, respectively, and revenue and net profit increased by 38%